Amyris, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amyris, Inc. - overview
Established
2003
Location
Emeryville, CA, US
Primary Industry
Biotechnology
About
Amyris, Inc. specializes in providing sustainable biotechnology solutions that transform plant-derived sugars into high-performing molecules, serving multiple industries with innovative and renewable chemistry. Founded in 2003 and headquartered in Emeryville, US, Amyris, Inc. focuses on biotechnology applications to create renewable chemical solutions.
CEO Fleur Insley leads the company, which has undergone various strategic pivots since its inception. The latest funding round, a RESTRUCTURING in which USD 190. 00 mn was raised from Foris Ventures, contributed to a total amount raised of USD 190. 00 mn.
Amyris has completed 22 deals, with the most recent deal dating back to May 27, 2015. Amyris specializes in utilizing innovative biotechnology to transform plant-derived sugars into high-performing molecules, which serve as the foundation for various products in multiple industries. The company's core offerings are built upon precision-engineered renewable chemistry, enabling the creation of sustainable solutions that cater to diverse applications, including personal care, cosmetics, and industrial biotechnology. Amyris' robust platform allows clients to access sophisticated biochemical processes, facilitating product differentiation and competitive advantages.
The clientele includes global companies seeking sustainable alternatives to traditional chemicals, with end users spanning across North America, Europe, and Asia. By unlocking new market opportunities through their advanced fermentation technology, Amyris is positioned as a leader in renewable biological chemistry. In 2022, Amyris reported revenue of USD 269. 84 mn while incurring an EBITDA loss of USD 541.
71 mn. The company generates revenue through strategic partnerships and collaborations, focusing on a business-to-business (B2B) model by providing customized products and services directly to clients. Revenue is derived from the sale of flagship products, which are developed through proprietary fermentation processes, tailored to meet specific needs of their partners, and structured with pricing agreements that reflect each client's unique requirements. Amyris plans to leverage its recent funding to expand into new markets and develop new products.
The company is focusing on designing next-generation products aimed at enhancing its offerings in sustainable personal care and industrial applications. Specific geographic regions targeted for expansion include Europe and Asia. The funding garnered from the latest RESTRUCTURING will support these initiatives and facilitate the growth of the company's market presence.
Current Investors
Foris Ventures, Total Gas & Power USA, Great American Capital Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.amyris.com
Verticals
Clean Technology
Company Stage
Mature
Total Amount Raised
Subscriber access only
Amyris, Inc. - timeline of key events
Amyris, Inc. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 73,694,000 | 41,119,000 | 43,274,000 | 34,153,000 | 67,192,000 | 143,445,000 | 63,604,000 | 152,557,000 | - | - | - |
| % Revenue Growth (YoY) | - | (44.2%) | 5.2% | (21.1%) | 96.7% | 113.5% | (55.7%) | 139.9% | - | - | - |
| EBITDA (USD) | (185,494,000) | (99,294,000) | (74,878,000) | (77,054,000) | (70,105,000) | (15,667,000) | (115,060,000) | (104,712,000) | - | - | - |
| Operating Income (USD) | (201,822,000) | (119,616,000) | (99,828,000) | (148,533,000) | (95,924,000) | (39,515,000) | (136,583,000) | (121,890,000) | - | - | - |
| Operating Margin | (273.9%) | (290.9%) | (230.7%) | (434.9%) | (142.8%) | (27.5%) | (214.7%) | (79.9%) | - | - | - |
| % EBITDA Margin | (251.7%) | (241.5%) | (173.0%) | (225.6%) | (104.3%) | (10.9%) | (180.9%) | (68.6%) | - | - | - |
| NET Income (USD) | (206,033,000) | (234,907,000) | 2,167,000 | (218,052,000) | (97,334,000) | (72,329,000) | (230,235,000) | (242,767,000) | - | - | - |
| % Net Margin | (279.6%) | (571.3%) | 5.0% | (638.5%) | (144.9%) | (50.4%) | (362.0%) | (159.1%) | - | - | - |
Amyris, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Carve Out | Completed | JVN Hair | - | ||||||||
| Restructuring | Completed | Amyris, Inc. | - | ||||||||
| Growth | Completed | Amyris do Brasil | - |
Displaying 1 - 3 of 3
Amyris, Inc. - employee data
Amyris, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member Board of Directors | BM | ||||||
| Chairman Of The Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.